LEIDEN – Pandemic preparedness rests on having a robust surveillance system to identify health threats – something that is still “rudimentary” in many African countries, says Professor Salim Abdool Karim, a South African infectious diseases epidemiologist. Describing monkeypox as a threat to health security in Africa, Karim said that it was important that health services […] Continue reading ->
The United States is considering shifting to intradermal injections of Monkeypox vaccine that could potentially stretch one dose of the approved MVA-BN vaccine, available only in limited quantities, into five doses, said US Food and Drug Administration Commissioner Robert Califf on Thursday. He was speaking at a press briefing minutes after Xavier Becerra, US Secretary […] Continue reading ->
Twelve African nations have joined with the United Nations and other international organizations in forming a new alliance that will work to prevent new infant HIV infections and to ensure no child living with HIV is denied treatment by the end of the decade. Proponents of the new Global Alliance for Ending AIDS in Children […] Continue reading ->
The manufacturer of the world’s only vaccine approved for monkeypox, Bavarian Nordic, closed its European vaccine production plant this spring and won’t reopen again until late 2022 – leading to a global monkeypox vaccine shortage, Health Policy Watch has learned. With only 16.4 million doses of the MVA-BN vaccine available worldwide, it is unclear how […] Continue reading ->
MONTREAL – Activists took over the stage at the opening of the International AIDS conference in Montreal on Friday morning to protest Canada’s denial of visas to hundreds of delegates, primarily from Africa, and the inequality and lack of funding that is driving new HIV infections. South African activist Vuyiseka Dubula, former head of the […] Continue reading ->
MONTREAL – Ninety countries will benefit from a voluntary licensing agreement announced on Thursday that will enable generic companies to produce a long-acting injectable antiretroviral, cabotegravir (CAB-LA), to protect people from HIV infection. CAB-LA’s manufacturer, UK pharmaceutical company ViiV, has given the license to the Medicines Patent Pool (MPP) for patents in least-developed, low-income, lower-middle-income […] Continue reading ->